Skip to main content
Research

CBD and Tourette Syndrome: What the Trials Actually Show

Echo 🌀2026-11-1212 min read
CBD and Tourette Syndrome: What the Trials Actually Show

A tic is not a habit and not a character flaw. It arrives as an urge that builds until it is expressed, a blink, a sniff, a head jerk, a word. Then it pauses and comes back. For the person living with it, the movement is often the smaller problem. The larger one is the room. The staring on the bus, the teacher who decides the child is doing it for attention, the colleague who asks whether it is contagious, the interview where a shoulder shrug becomes the entire conversation.


That social cost explains why the market around tics is unusually loud. Desperation creates demand and demand creates sellers. Search for Tourette syndrome and you will find CBD oils promising calm, gummies marketed for tics and stimming, and parents in forums trading CBD doses by body weight. Against that noise sits a real but narrow evidence base, and most of it tests a medicine that is not CBD on its own.


This article separates the strands. It covers the 2023 trial in NEJM Evidence, the 2023 crossover study of cannabis in adults, and the systematic review that found the tic data thin. It also covers what matters more, which is diagnosis, behavioural therapy, and the reason tics belong with a neurologist.

Why Tics Are Not Like Other Symptoms

Most symptoms people self treat with CBD are subjective. Pain, anxiety, and poor sleep are reported by the patient, scored by the patient, and judged improved by the patient. Tics are visible, and that changes how evidence gets made and misread.


Visible symptoms look measurable, so any CBD seller can claim an effect. Record a video before and after, put the clips side by side, and you have a testimonial that feels like data. The problem is that tics fluctuate across weeks and months, they worsen with stress, fatigue, and excitement, and they are strongly suggestible. Watch someone else tic and yours may increase. Sit still in a calm room and yours may settle. A natural waxing and waning curve can impersonate a treatment response with no drug involved.

What Tourette Syndrome Actually Is

Tourette syndrome is a neurodevelopmental condition defined by multiple motor tics and at least one vocal tic, present for more than a year, with onset in childhood. The threshold is about pattern and duration, not severity. Plenty of people meet the criteria and are barely bothered. Some are disabled by it.


Two clinical facts shape what follows. Most children improve through adolescence, and a minority carry impairing tics into adult life. Severity is also not impairment. A person with frequent tics who works, sleeps, and socialises is not automatically a candidate for drug treatment, while someone with fewer tics and severe social withdrawal may be.


Comorbidity is the rule rather than the exception. Obsessive compulsive symptoms and attention deficit hyperactivity are common alongside tics, and both can drive more impairment than the tics themselves. Our article on CBD and OCD and the one on CBD and ADHD go deeper, because treating those conditions often reduces the tic burden indirectly.

The Trial Everyone Cites

The study that changed this conversation appeared in 2023 in NEJM Evidence. It was a randomised, double blind, placebo controlled, multicentre trial run in Germany, and it enrolled roughly one hundred adults with moderate to severe Tourette syndrome. Participants received an oral extract containing THC and CBD, or placebo, over a treatment phase of several weeks, with tic severity scored on the Yale Global Tic Severity Scale.


The primary endpoint was the change in total tic score. The combination product outperformed placebo, and the difference was statistically significant. Motor and vocal tics both moved in the same direction. That is a genuine result from a design that controls for expectation, and it is the strongest single piece of evidence in this field.


Adverse events were more frequent on active treatment. Somnolence, dizziness, dry mouth, and attention difficulties were the recurring themes, most were mild to moderate, and a proportion of participants stopped treatment because of them. In a condition where the alternative drugs include antipsychotics, that profile is not disqualifying. It is also not trivial.

The Product Detail That Gets Lost

Here is the sentence most online summaries delete. The NEJM Evidence trial did not test CBD. It tested a combination of tetrahydrocannabinol and cannabidiol, in an oral solution, pharmaceutical grade, precisely dosed, and titrated under medical supervision.


That distinction is not pedantry. THC is the cannabinoid that produces intoxication, and it carries its own risks, including anxiety, dissociation, cognitive effects, and psychiatric risk in vulnerable people. A trial of a THC and CBD extract tells you about that extract. It does not tell you that a CBD isolate, a broad spectrum oil with trace THC, or a gummy from a petrol station will reduce tics. As of writing, no randomised trial has tested CBD on its own for tics at all.


The mechanism is probably not a CBD mechanism either. Cannabinoid signalling in the basal ganglia and cortico striatal circuits is a plausible substrate for tic modulation, and THC is the component with the strongest activity at CB1 receptors in those circuits. When a headline says CBD helped tics, the underlying study usually tested something else.

What That Result Does Not Mean

A statistically significant mean difference is a statement about groups. It is not a promise to an individual, and it is not a cure. That is an unglamorous sentence in a CBD market which prefers certainty.


Tic scores fell in the placebo arm too, which is expected in a fluctuating, suggestible condition assessed by raters who hope to see improvement. The average advantage for active treatment was a modest number of points on a scale where the maximum is far higher. Averages hide non responders, and in a trial of this size the proportion who gained nothing is invisible in the headline figure.


The trial was short. It was conducted in adults, which matters for a condition that begins in childhood. It did not measure school attendance, employment, or social participation as primary outcomes. And it cannot speak to what happens after a year of daily cannabinoid exposure, because nobody was followed that long.

The Crossover Trial in Adults

A second adult study appeared in 2023 in Cannabis and Cannabinoid Research. It used a double blind, randomised, crossover design, so each participant received active cannabis and placebo in random order, with tic severity compared within the same person. That design is attractive when between person variability is large, because everyone acts as their own control.


The direction of the result was consistent with the German trial. Tic severity was lower during active treatment than during placebo. The design also brings weaknesses, and they are worth naming.


Crossover trials in psychoactive drugs struggle with blinding. Participants who have used cannabis can often tell which phase they are in, and belief changes reporting. Carryover is a second problem, since the washout has to clear the drug and the expectation. A small sample magnifies both. The study adds coherence. It does not add certainty.

The Systematic Review That Found Thin Data

Also in 2023, a systematic review in Pharmacology Biochemistry and Behavior examined CBD trials across neurodevelopmental disorders, including autism, ADHD, and Tourette syndrome. Its finding on tics was blunt. The literature is small, heterogeneous, and mostly uncontrolled.


Concretely, that means case series, chart reviews, and open label studies where everyone knows what they are taking. Doses ranged widely and products differed in ratio and route. Tic severity was often a secondary observation rather than a prespecified endpoint, and populations were mixed, so a study of autistic children with irritability might report tics as an incidental finding.


A review in that situation cannot pool data into a confident estimate. It can only describe a signal and recommend better trials. That is what it did, and it is the correct conclusion. Anyone citing this paper as proof that CBD treats tics has not read past the abstract.

Where Reviews Put Cannabinoids in Practice

A 2024 review in Pharmacopsychiatry asked what a clinician should actually do, rather than what a mechanism might suggest. On Tourette syndrome, the position is narrow and conditional.


Cannabinoids, and specifically THC containing preparations, are framed as a possible option in selected adults whose tics remain impairing after standard treatment, managed by a specialist who can monitor psychiatric risk. They are not first line. They are not for casual use. They are not a substitute for behavioural therapy.


The same review flags the cautions that matter. Personal or family history of psychosis, heavy substance use, pregnancy, and adolescence all shift the risk balance. So does driving, since sedation and slowed reaction time are the most common adverse effects of the product that showed benefit. That review offers no support for a CBD product sold for tics.

Why Formulation Changes the Answer

A 2025 paper in Cannabis and Cannabinoid Research compared different cannabinoid formulations in anxiety related disorders, and the lesson transfers to tics even though the population differs. Formulation is not a packaging detail. It changes the drug.


An isolate contains CBD and nothing else. A broad spectrum oil contains other plant cannabinoids without THC. A full spectrum oil contains THC, sometimes at a level that accumulates with daily use. Oral absorption is slow and variable, and taking CBD oil with food changes exposure. Inhaled cannabis has a completely different pharmacokinetic profile from a capsule.


So the question of whether CBD helps tics is malformed. The honest version is whether this specific product, at this dose, in this person, over this duration, does more good than harm. The trials answer that for one pharmaceutical extract. Everything else is extrapolation.


A 2026 review in eClinicalMedicine assessed the safety and effectiveness of medical cannabis across conditions using real world data, and its conclusions were unromantic. Average benefits are modest, adverse events are common, and evidence quality varies by indication. Real world data capture patients that trials exclude, and they also attract selection and expectation, since people who pay for a private prescription and report back are not a neutral sample. For tics, the subgroup data stay thin.

Why Paediatric Data Are the Weakest

Tics begin in childhood, which is exactly where the CBD evidence is thinnest.


The substantial paediatric CBD literature is in epilepsy, using high doses with close monitoring, and even there the safety profile includes liver enzyme rises and drug interactions. That work does not transfer to tics, to lower doses, or to over the counter oils.


In tics, the paediatric literature is largely case reports and small open label series. There are no adequately powered randomised trials in children, no long term developmental safety data, and no basis for a CBD dose recommendation. This is not a gap a parent can fill by reading forum posts.


The developing brain is a specific concern with THC. Adolescence is the period when cannabis exposure has been most consistently associated with later psychotic symptoms and cognitive effects, and the causality debate there is still live. Adding a psychoactive cannabinoid to a teenager for a condition that usually improves on its own is a decision with an unfavourable risk balance in most cases.

The Interaction Problem Nobody Mentions

Tics rarely occur alone, and the drugs used to treat them travel the same liver pathways that CBD interferes with.


CBD inhibits CYP3A4 and CYP2C19, and it affects the P glycoprotein transporter. Aripiprazole and risperidone, both used for tics, are cleared through those routes. So are many antidepressants and stimulants. Adding CBD can raise the blood level of a drug that was carefully titrated, and the result may be sedation, tremor, or a movement side effect that gets misread as worsening tics.


Clonidine and guanfacine, the alpha 2 agonists commonly used first, add sedation on top of sedation. Valproate and lamotrigine have narrow enough windows that pharmacokinetic shifts matter. Our article on CBD drug interactions sets out the full list and the mechanisms, and it is the section to read before anyone in this situation adds a cannabinoid to an existing regimen.

The Safety Question You Can Answer

The safety issues with CBD are not mysterious, and they are mostly about the product rather than the molecule.


At higher doses, CBD can raise liver transaminases, which matters more in a person already on hepatically cleared medication. Somnolence and gastrointestinal upset are common. Labelling accuracy is a persistent problem, with analyses repeatedly finding products that contain more or less than the stated amount, or contain THC when they claim not to. Heavy metals, pesticides, and solvent residues appear in independent testing often enough to make batch level certificates necessary rather than reassuring.


None of that makes CBD dangerous in absolute terms. It makes unmonitored CBD use in a child with a neurological condition a poor bet. Our CBD safety overview covers dosing ranges, liver monitoring, and the questions to ask about a certificate of analysis.

Why Tics Need a Neurologist

The single most useful thing anyone can do with a new tic is get the diagnosis right.


Not every movement is a tic. Myoclonus, dystonia, chorea, and stereotypies look different to a trained eye and have different causes. Sudden onset of complex tic like movements in a teenager, often with vocalisations that resemble social media content, has become a recognised presentation of functional neurological disorder, and it is managed differently from Tourette syndrome. Treating that presentation with CBD delays the right care.


Once the diagnosis is clear, treatment is stepped and conditional. Education and reassurance come first, because understanding the condition reduces impairment on its own. Comprehensive behavioural intervention for tics, a structured therapy built on habit reversal and exposure principles, is first line for impairing tics and has good evidence behind it. Medication comes next, typically an alpha 2 agonist, then a low dose antipsychotic, with the choice driven by comorbidity and side effect tolerance. Treating coexisting ADHD or OCD often helps the tics more than attacking the tics directly.


Cannabinoids sit at the far end of that sequence, in adults, after standard options have been tried. That is where the Pharmacopsychiatry review puts them, and it is what the trial evidence supports. No CBD product can replace that sequence.

Red Flags in Online Tic Claims

A short list, because the pattern is predictable.


Claims of a cure for Tourette syndrome are false, since the condition is neurodevelopmental and its course is variable. Before and after videos prove nothing in a fluctuating, suggestible condition. Testimonials from parents who started a CBD product during a good period are not evidence. Dose calculators for children based on body weight are invented, because no paediatric dose finding study exists to support them. The phrase pharmaceutical grade applied to an unregulated supplement is marketing. A certificate of analysis without a batch number matching the bottle is decoration.


The tell is always the same. Real evidence describes limits. Marketing describes certainty.

What to Ask a Neurologist

Bring questions rather than a bottle.


Ask whether the diagnosis is confirmed and what else was considered. Ask whether treatment is indicated at all, given impairment rather than the tic count. Ask how to access behavioural therapy, since waiting lists are the real barrier in most health systems. Ask whether any current medication is a CYP3A4 substrate and whether adding an inhibitor would change monitoring. Ask, if CBD or a THC containing medicine is being considered, which product, at what ratio, with what follow up.


A good answer will separate three things that get muddled. The mechanism is plausible. The adult evidence is real but narrow and involves THC. The decision for one person is a clinical judgment about risk, comorbidity, and alternatives.

The Bottom Line

The honest summary fits in a few sentences. One well conducted trial showed that a pharmaceutical THC and CBD oral solution reduced tic severity in adults with Tourette syndrome, with a side effect profile that is manageable under supervision. A second adult study pointed the same way. A systematic review found the wider CBD literature too thin to support a recommendation, and later reviews place cannabinoids at the end of a treatment pathway that begins with diagnosis and behavioural therapy.


That is a meaningful result for adults with impairing tics and no good options. It is not a licence to treat a child with a CBD oil from a website, and it is not a cure for a condition that most people grow out of. Tics change over months on their own, which is why the placebo arm always improves and why anecdotes are so persuasive.


If you or your child has tics, the sequence is unglamorous and effective. Get a proper diagnosis. Ask about behavioural therapy before any drug. Review the medication list for interactions. And if cannabinoids come up at all, let them come up in a specialist appointment, as a medicine with a ratio and a dose, not as a wellness product with a promise.

Find Your Perfect CBD Product

Take our 2-minute quiz to get personalized recommendations based on your needs.

Take the Quiz →
CBDTourette SyndromeTicsResearch

Disclaimer: This article is for informational purposes only and does not constitute medical advice. CBD products are not FDA-approved to treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before starting any new supplement, especially if you have a medical condition or take medications.